Antibody response to inactivated influenza a (H1N1) 2009 monovalent vaccine in patients with and without HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 3, 2011, Pages

  Tiu, Ceres T ^a   Lin, Yu Shia ^a   Pagala, Murali ^a   Ghitan, Monica ^a   Treanor, John J ^b   Fitzgerald, Theresa ^b   Xiao, Ying Yi ^a   Ushumirskiy, Stan ^a   Wong, San S ^a   Javier, Emilio M ^a   Xu, Yiqing ^a   Minkoff, Howard L ^a   Chapnick, Edward K ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LETTER; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEROCONVERSION; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80054945499     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318232b50e     Document Type: Letter

References (21)

1. Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58:467.
2. World Health Organization. Pandemic (H1N1) 2009-update 67. Available at: http://www.who.int/csr/don/2009-09-25/en/index. html. Accessed Oct 3, 2009.
3. World Health Organization. World now at the start of 2009 influenza pandemic. Available at: http://www.who.int/mediacentre/news/statements/2009/ h1n1-pandemic-phase6-20090611/en/index.html. Accessed October 3, 2009.
4. World Health Organization. Global alert and response, pandemic (H1N1) 2009-update 112. Available at: http://www.who.int/csr/don/2010-08-06/en/index. html. Accessed October 16, 2010.
5. Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York City. Clin Infect Dis. 2010;50:1498-1504.
6. Use of influenza A (H1N1) 2009 monovalent vaccine, recommendations of the advisory committee on immunization practices (ACIP), 2009. MMWR Recomm Rep. 2009; 58(RR10):1-8.
7. Centers for Disease Control and Prevention. Key facts about 2009 H1N1 flu vaccine. Available at: http://cdc.gov/h1n1flu/vaccination/vaccine-keyfacts.htm. Accessed October 16, 2010.
8. Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIVinfected persons, a randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 1999;131:430-433. (Pubitemid 29444433)
9. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with Human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011;52: 128-137.
10. Yamanaka H, Teruya K, Tanaka M, et al. The HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1 infected patients. J Acquir Immune Defic Syndr. 2005;39: 167-173. (Pubitemid 40741114)
11. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18: 3040-3049. (Pubitemid 30303809)
12. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361: 2405-2413.
13. Xu Y, Methuku N, Coimbatore P, et al. A prospective study of the immunogenicity of inactivated influenza A (H1N1) 2009 monovalent vaccine in patients who have solid or hematologic malignancies. Presented at: Abstracts of the 48th Infectious Diseases Society of America Annual Meeting; October 21-24, 2010; Vancouver, Canada. Abstract LB-13.
14. Flynn P, Nachman S, Spector S, et al. Safety and immunogenicity of 2009 H1N1 influenza immunization in HIV-1 perinatally infected children and youth. Presented at: Abstracts of the 48th Infectious Diseases Society of America Annual Meeting; October 21-24, 2010; Vancouver, Canada Abstract LB-40.
15. Weinberg A, Muresan P, Fenton T, et al. Safety and immunogenicity of two doses of monovalent pandemic H1N1 (pH1N1) influenza vaccine in HIV-infected pregnant women. Presented at: Abstracts of the 48th Infectious Diseases Society of America Annual Meeting; October 21-24, 2010; Vancouver, Canada. Abstract LB-14.
16. Tebas P, Frank I, Lewis M, et al. The Center for AIDS Research and Clinical Trials Unit of the University of Pennsylvania. Poor Immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24:2187-2192.
17. US. Food and Drug Administration Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. Available at: www.fda.gov/BiologicsBlood-Vaccines/GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm074786. html. Accessed August 8, 2010.
18. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:1-62.
19. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with Acquired Immunodeficiency Syndrome. Arch Intern Med. 2001;161:441-446. (Pubitemid 32116562)
20. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52:138-146.
21. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52:122-127.